Comparison of efficacy and safety in JAK inhibitor ─ Tofacitinib vs Baricitinib ─

DOI
  • Yoshii Ichiro
    Department of Rheumatology and Musculoskeletal Medicine, Yoshii Hospital

Bibliographic Information

Other Title
  • 当院投与例におけるJAK阻害剤の効果比較─ Tofacitinib対Baricitinib ─

Search this article

Abstract

<p>［Objective］</p><p>We retrospectively compared the efficacy and safety between two major Janus kinase inhibitors（JAK-i）administered to patients with rheumatoid arthritis.</p><p>［Methods］</p><p>RA patients to whom JAK-i were administered and followed up for 12 months or more were tracked. Patients were divided into two groups according to the JAK-i used: Tofacitinib（TOF）and Baricitinib（BAR）. Their clinical parameters were statistically compared from baseline to 12 months after baseline. Statistical significance was determined to be less than 5%.</p><p>［Results］</p><p>A total of 53 cases were studied. These included 22 TOF and 31 BAR. Female distributions were 72.7% and 71.0%. Average values of age, disease duration, anti-cyclic citrullinated polypeptide antibodies, rheumatoid factor（RF）titer, Sharp/van der Heijde Score（SHS）, DAS28-CRP, HAQ-DI, pain VAS, and MMP-3 in the TOF and the BAR were 69.1 and 69.4, 5.5 and 7.5 years, 311.2 and 456.5U/L, 179.1 and 279.5IU/L, 50.2 and 69.1, 3.48 and 3.26, 0.773 and 0.726, 39.7 and 31.0mm, and 189.1 and 141.3ng/mL, respectively. There was no significant difference in the parameters between the two groups. However, as a sub-analysis, DAS28-CRP in the sub-group with a disease duration of 10 years or more and with SHS of 100 or more decreased significantly than in the lesser group for each parameter in the TOF. Though no significant difference was demonstrated, eGFR in BAR tends to decrease after baseline compared to that in TOF.</p><p>［Conclusions］</p><p>As characteristics in action differ for each JAK-i, the appropriate drug should be chosen based on these drug characteristics.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top